Compare GUT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GUT | TRDA |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.5M | 500.4M |
| IPO Year | N/A | 2021 |
| Metric | GUT | TRDA |
|---|---|---|
| Price | $6.19 | $6.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 185.7K | ★ 577.1K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | N/A | $50.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.32 | $4.93 |
| 52 Week High | $6.33 | $16.45 |
| Indicator | GUT | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 29.05 |
| Support Level | $6.11 | $5.58 |
| Resistance Level | $6.31 | $6.90 |
| Average True Range (ATR) | 0.07 | 0.97 |
| MACD | -0.01 | -0.55 |
| Stochastic Oscillator | 37.21 | 3.88 |
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.